

PRODUCT INFORMATION



N-desmethyl Rosuvastatin (sodium salt hydrate)

Item No. 26682

Formal Name: (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid, disodium salt, monohydrate

MF: $C_{21}H_{24}FN_3O_6S \cdot 2Na [H_2O]$


FW: 529.5

Purity: $\geq 95\%$

Supplied as: A solid

Storage: $-20^{\circ}C$

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

N-desmethyl Rosuvastatin (sodium salt hydrate) is supplied as a solid. A stock solution may be made by dissolving the N-desmethyl rosuvastatin (sodium salt hydrate) in the solvent of choice, which should be purged with an inert gas. N-desmethyl Rosuvastatin (sodium salt hydrate) is slightly soluble in methanol and DMSO (warmed).

N-desmethyl Rosuvastatin (sodium salt hydrate) is slightly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

N-desmethyl Rosuvastatin is an active metabolite of the HMG-CoA reductase inhibitor rosuvastatin (Item No. 18813).^{1,2} N-desmethyl Rosuvastatin is formed when rosuvastatin undergoes demethylation, primarily by the cytochrome P450 (CYP) isoform CYP2C9 and to a lesser extent by CYP2C19 and CYP3A4.¹

References

1. Macwan, J.S., Ionita, I.A., and Akhlaghi, F. A simple assay for the simultaneous determination of rosuvastatin acid, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). *Anal. Bioanal. Chem.* **402**(3), 1217-1227 (2012).
2. Bai, X., Wang, X.P., He, G.D., et al. Simultaneous determination of rosuvastatin, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma by UPLC-MS/MS and its application to clinical study. *Drug Res. (Stuttg.)* **68**(6), 328-334 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/20/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM